StockNews.AISignal intelligence
Company intelligence

HCA

HCA Healthcare, Inc. · NYSE · Healthcare

Price$511.78+2.55% · +$12.73
Market cap106.91BEquity value
P / E17.7Trailing ratio
Volume1.05MLatest session
Market data

HCA price chart

TradingView
Related signals
1 min delayed

Browse public HCA signals with their source context and measured market impact. Open any signal for its permanent analysis page.

HCAOct 28, 2026+5.71% since signal

HCA raises 2026 guidance after strong Q3; analysts lift price targets

HCA Healthcare posted a stronger-than-expected Q3 with revenue of $19.849B and adjusted EPS of $7.22, topping estimates. The company raised its FY2026 guidance for both earnings and sales, signaling durable profitability despite policy headwinds. The upbeat results, along with higher target prices from multiple banks, may support near-term upside and a re-rating of the stock.

View signal analysis
HCAOct 27, 2026+3.88% since signal

HCA Q3 beat; raises 2026 guidance amid payer mix headwinds

HCA reported a solid Q3 with revenue and EBITDA above estimates and adjusted earnings of $7.22 per share, driving a raised FY2026 guidance. However, uninsured volume created a roughly $400 million payer-mix drag, offset by gains in insured revenue per admission and cost improvements. The company cautioned on Medicaid payment tailwinds amid policy fluidity, suggesting near-term stock pressure despite durable fundamentals.

View signal analysis
HCASep 23, 2026-2.43% since signal

BMO Initiates HCA with Outperform and $495 Target

BMO Capital began covering HCA with an Outperform rating and a $495 price target, signaling confidence in the hospital operator's growth prospects. With HCA trading around $438, the target implies roughly 13% potential upside over the next year, possibly attracting funds and support for multiple expansion as analysts react.

View signal analysis
HCAJul 22, 2026+0.89% since signal

Portnoy Law Investigation Adds Legal Risk as HCA Downgrades 2026 Outlook

On July 14, 2026, HCA disclosed a substantial downgrade to FY2026 guidance due to a weaker payer mix from rising uninsured visits, lowering EPS to $28.70–$30.50 and revenue to $77–$79.5B, with EBITDA of $15.4–$16.1B. The stock closed down 6.95% to $363.60. Later, The Portnoy Law Firm announced a securities-fraud investigation, potentially adding litigation risk to an already challenged outlook.

View signal analysis
Research

Company intelligence